Pertuzumab and trastuzumab: the rationale way to synergy
It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer...
Salvato in:
| Pubblicato in: | Anais da Academia Brasileira de Ciências |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Academia Brasileira de Ciências
2016
|
| Soggetti: | |
| Accesso online: | https://www.redalyc.org/articulo.oa?id=32746362012 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|